연구성과로 돌아가기
2021 연구성과별 연구자 정보 (203 / 2991)
※ 현재 Web of Science 저자 정보만 집계되어 있습니다.
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Document Title | Author Full Name | Author Short Name | Index | Corresponding | Address | ResearcherID | ResearcherID Author Name | ORCID | ORCID Author Name | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
| ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma | Lim, Hyeong-Seok | Lim, HS | 24 | Univ Ulsan, Asan Med Ctr, Dept Clin Pharmacol & Therapeut, Coll Med, Seoul, South Korea | AAX-4732-2020 | Lim, Hyeong-seok | twkimmd@amc.seoul.kr;shivam@gene.com; | |||
| ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma | Kim, Kyu-Pyo | Kim, KP | 25 | Univ Ulsan, Asan Med Ctr, Dept Oncol, Coll Med, Seoul, South Korea | twkimmd@amc.seoul.kr;shivam@gene.com; | |||||
| ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma | Kim, Yu Jung | Kim, YJ | 26 | Seoul Natl Univ, Bundang Hosp, Dept Internal Med, Div Hematol & Med Oncol,Coll Med, Seongnam, South Korea | twkimmd@amc.seoul.kr;shivam@gene.com; | |||||
| ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma | Han, Hye Sook | Han, HS | 27 | Chungbuk Natl Univ, Chungbuk Natl Univ Hosp, Dept Internal Med, Coll Med, Cheongju, South Korea | twkimmd@amc.seoul.kr;shivam@gene.com; | |||||
| ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma | Lee, Soo Jung | Lee, SJ | 28 | Kyungpook Natl Univ, Chilgok Hosp, Dept Oncol Hematol, Daegu, South Korea | twkimmd@amc.seoul.kr;shivam@gene.com; | |||||
| ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma | Kim, Seung Tae | Kim, ST | 29 | Sungkyunkwan Univ, Samsung Med Ctr, Div Hematol Oncol, Seoul, South Korea | twkimmd@amc.seoul.kr;shivam@gene.com; | |||||
| ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma | Jung, Minkyu | Jung, M | 30 | Yonsei Univ, Dept Internal Med, Div Med Oncol, Coll Med, Seoul, South Korea | ACI-8824-2022 | KANG, MIN KYU | 0000-0001-8281-3387 | Jung, Minkyu | twkimmd@amc.seoul.kr;shivam@gene.com; | |
| ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma | Hong, Yoon-hee | Hong, YH | 31 | Hanmi Pharmaceut Co Ltd, Dept Clin Res & Dev, Seoul, South Korea | twkimmd@amc.seoul.kr;shivam@gene.com; | |||||
| ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma | Noh, Young Su | Noh, YS | 32 | Hanmi Pharmaceut Co Ltd, Dept Clin Res & Dev, Seoul, South Korea | twkimmd@amc.seoul.kr;shivam@gene.com; | |||||
| ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma | Choi, Munjeong | Choi, M | 33 | Hanmi Pharmaceut Co Ltd, Dept Clin Res & Dev, Seoul, South Korea | twkimmd@amc.seoul.kr;shivam@gene.com; | |||||
| ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma | Han, Oakpil | Han, O | 34 | Hanmi Pharmaceut Co Ltd, Dept Clin Res & Dev, Seoul, South Korea | twkimmd@amc.seoul.kr;shivam@gene.com; | |||||
| ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma | Nowicka, Malgorzata | Nowicka, M | 35 | Genentech Inc, Dept Oncol Biomarker Dev, San Francisco, CA 94080 USA | twkimmd@amc.seoul.kr;shivam@gene.com; | |||||
| ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma | Srinivasan, Shrividhya | Srinivasan, S | 36 | Genentech Inc, Dept Oncol Biomarker Dev, San Francisco, CA 94080 USA | twkimmd@amc.seoul.kr;shivam@gene.com; | |||||
| ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma | Yan, Yibing | Yan, YB | 37 | Genentech Inc, Dept Oncol Biomarker Dev, San Francisco, CA 94080 USA | twkimmd@amc.seoul.kr;shivam@gene.com; | |||||
| ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma | Kim, Tae Won | Kim, TW | 38 | 교신저자 | Univ Ulsan, Asan Med Ctr, Dept Oncol, Coll Med, Seoul, South Korea | GRX-7323-2022 | Kim, Tae Won | twkimmd@amc.seoul.kr;shivam@gene.com; |
페이지 이동: